Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SUNOSI safely and effectively. See full prescribing information for SUNOSI. SUNOSI® (solriamfetol) tablets, for oral use, CIV Initial U.S. Approval: 2019
Medication labelWhy this: Advisory · dailymed-prescription
SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) [see Clinical Studies (14)] . Limitations of Use SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with SUNOSI. SUNOSI is not a substitute for these modalities.
- generic_name
- solriamfetol
- product_names
- solriamfetol
- ndc
- 81968-350, 81968-351, 81968-350-01, 81968-350-07, 81968-350-10, 81968-351-01, 81968-351-07, 81968-351-10
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en